Once marginalized, psychedelics and alternative therapies in psychiatry are now being re-evaluated through a scientific lens for their potential to treat resistant mental health conditions. Clinical trials using psilocybin, MDMA, and ketamine have shown promise in reducing symptoms of depression, PTSD, and end-of-life anxiety when paired with guided psychotherapy. These treatments often work differently from conventional medications, targeting neuroplasticity and emotional processing. Integration into psychiatric practice remains cautious but optimistic, with safety protocols, legal frameworks, and therapist training being carefully developed. Beyond psychedelics, interest in holistic alternatives like nutritional psychiatry, acupuncture, and neurofeedback is also growing. As the evidence base expands, psychiatry is beginning to embrace a more diverse toolkit that respects both scientific rigor and patient-centered preferences for innovative, individualized treatment.
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States